Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2026-08-03 16:20:53 ET · period of report 2026-07-30 · accession 0001470831-26-000745 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-03 16:20 | 2026-07-30 | BBIO | Apuli Maricel | CAO | S - Sale | $80.06 | -2,000 | 127.4K | -2% | -$160.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-30 | S | D | 2,000 | $80.06 | 127,401 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. |